Kostas Biliouris
Stock Analyst at BMO Capital
(0.88)
# 3,696
Out of 4,761 analysts
50
Total ratings
26.19%
Success rate
-15.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $32.32 | +39.23% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $12.17 | +310.85% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $5.93 | +473.36% | 3 | Jan 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $16.63 | +110.46% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $2.36 | +620.34% | 2 | Aug 15, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $4.64 | +762.07% | 4 | Jul 18, 2024 | |
| LEGN Legend Biotech | Maintains: Outperform | $90 | $39.70 | +126.70% | 3 | Jul 3, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $234 | $250.59 | -6.62% | 4 | Jun 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $170 → $200 | $106.28 | +88.18% | 4 | Jun 24, 2024 | |
| KRRO Korro Bio | Maintains: Outperform | $120 | $26.29 | +356.45% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $30.43 | +87.32% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $36.85 | +0.41% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $4.79 | +1,298.75% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $68.25 | +46.52% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $2.97 | +540.81% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $7.28 | +751.65% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $47.91 | +104.55% | 1 | Jun 17, 2022 |
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $32.32
Upside: +39.23%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $12.17
Upside: +310.85%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $5.93
Upside: +473.36%
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $16.63
Upside: +110.46%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $2.36
Upside: +620.34%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $4.64
Upside: +762.07%
Legend Biotech
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $39.70
Upside: +126.70%
Alnylam Pharmaceuticals
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $250.59
Upside: -6.62%
Sarepta Therapeutics
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $106.28
Upside: +88.18%
Korro Bio
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $26.29
Upside: +356.45%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $30.43
Upside: +87.32%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $36.85
Upside: +0.41%
Jan 31, 2024
Initiates: Outperform
Price Target: $67
Current: $4.79
Upside: +1,298.75%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $68.25
Upside: +46.52%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $2.97
Upside: +540.81%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $7.28
Upside: +751.65%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $47.91
Upside: +104.55%